Meilleure Health International Industry Group Limited (2327) AI Stock Analysis

• Market Cap: HK$1.23B
• Dividend Yield: 1.31%
• Average Volume (3M): 966.50K
• Price to Earnings (P/E): 38.0
• Beta (1Y): 0.35
• Revenue Growth: -60.81%
• EPS Growth: -21.00%
• Country: HK
• Employees: 46
• Sector: Industrials
• Sector Strength: 90
• Industry: Conglomerates
• EPS (TTM): <0.01
• Shares Outstanding: 4,093,756,600
• 10 Day Avg. Volume: 513,000
• 30 Day Avg. Volume: 966,500
• PEG Ratio: 7.38
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: ―

Meilleure Health International Industry Group Limited receives a moderate score due to mixed financial performance characterized by volatility and operational challenges. While there is positive technical momentum, the high P/E ratio indicates potential overvaluation concerns. The stock's dividend yield offers some appeal, but not enough to significantly enhance its attractiveness. Overall, the stock presents a balanced risk-reward profile, with potential upside being tempered by financial instability.

Meilleure Health International Industry Group Limited Business Overview & Revenue Model

Company Description

Meilleure Health International Industry Group Limited, an investment holding company, engages in industrial hemp, healthcare-related, trading, agency service, property investment and leasing, and property development businesses in Hong Kong, the People's Republic of China, and internationally. The company is involved in the trading of construction materials; development and sale of residential properties; property investment and leasing activities; and sale of healthcare-related products. It also provides real estate agency services; cannabidiol downstream product application services; health management services, including anti-aging, aesthetic medicine, and other health consulting; and healthcare related product sales agency services. The company was formerly known as U-Home Group Holdings Limited and changed its name to Meilleure Health International Industry Group Limited in March 2017. Meilleure Health International Industry Group Limited is headquartered in Admiralty, Hong Kong.

How the Company Makes Money

Meilleure Health International Industry Group Limited generates revenue through multiple streams primarily centered around its health and wellness offerings. The company's revenue model includes the production and sale of health supplements and medical devices, which cater to a wide range of health needs. Additionally, it engages in providing health management services that support preventive care and wellness. Key partnerships with healthcare providers and distribution networks enhance its market reach and contribute significantly to its earnings. The company's focus on research and development also plays a crucial role in maintaining a competitive edge, allowing it to introduce new and improved products to the market.

Meilleure Health International Industry Group Limited Financial Statement Overview

Summary

Meilleure Health International Industry Group Limited shows a mixed financial performance with significant volatility across income, balance sheet, and cash flow metrics. While there are periods of profitability and positive cash flow, the inconsistency over the years suggests underlying operational challenges and financial instability.

Income Statement

The company has experienced significant fluctuations in revenue, with a notable decline from 2020 to 2024. Gross profit margin and net profit margin have been inconsistent, indicating volatility in profitability. The EBIT and EBITDA margins have similarly varied, pointing to operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a reasonable level of leverage. However, the equity ratio has been decreasing, which could suggest increasing liabilities relative to assets. Return on equity has been inconsistent, reflecting variability in profitability.

Cash Flow

Cash flow from operations has been unstable, with periods of negative cash flow. Free cash flow growth has been erratic, but the company has managed to maintain positive free cash flow in recent years. The operating cash flow to net income ratio suggests some challenges in translating income into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
50.68M	129.30M	119.89M	253.03M	265.13M
	Gross Profit
28.91M	78.09M	66.76M	100.93M	111.25M
	EBIT
1.76M	39.36M	54.65M	66.98M	52.06M
	EBITDA
56.52M	71.38M	58.50M	70.55M	59.97M
	Net Income Common Stockholders
32.48M	40.83M	17.82M	60.32M	83.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.49M	106.31M	217.28M	387.04M	281.28M
	Total Assets
1.67B	1.70B	1.71B	1.74B	1.70B
	Total Debt
303.06M	297.06M	249.13M	170.42M	154.84M
	Net Debt
266.57M	190.75M	38.14M	-102.17M	-78.63M
	Total Liabilities
467.29M	442.89M	384.18M	306.35M	299.60M
	Stockholders Equity
1.20B	1.25B	1.32B	1.43B	1.40B
Cash Flow		Free Cash Flow
188.62M	-137.32M	42.10M	-89.79M	70.39M
	Operating Cash Flow
188.75M	-136.49M	43.15M	-83.27M	70.81M
	Investing Cash Flow
-271.59M	53.72M	-134.76M	161.56M	108.14M
	Financing Cash Flow
3.87M	-18.90M	41.93M	-38.22M	-108.88M

Meilleure Health International Industry Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.29, and above the 200-day MA of 0.26, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.50 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2327.

Meilleure Health International Industry Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	$4.52B	12.34	5.41%	3.62%	4.15%	-12.18%
2327	57 Neutral	HK$1.23B	37.97	2.65%	1.31%	-60.81%	-21.00%
PIAIF		$127.30B	6.26		7.39%	―	―
SBMFF		$10.87B	46.27	6.14%	1.22%	―	―
CHKGF		$14.74B	7.83	3.52%	4.65%	―	―
CHSYF		$3.51B	10.08	10.17%	0.48%	―	―
NWSZF		$3.81B	11.51	5.29%	2.40%	―	―

Meilleure Health International Industry Group Limited Corporate Events

Meilleure Health Announces AGM and Share Repurchase Plan

Meilleure Health International Industry Group Limited has announced its upcoming annual general meeting scheduled for June 27, 2025, in Hong Kong. Key agenda items include the approval of the audited financial statements for 2024, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, a resolution will be considered to authorize the company’s directors to repurchase up to 10% of its shares, enhancing shareholder value and potentially impacting the company’s market position.

Meilleure Health Announces Final Dividend for 2024

Meilleure Health International Industry Group Limited announced a final ordinary cash dividend of HKD 0.004 per share for the financial year ending December 31, 2024. The dividend reflects the company’s financial performance and commitment to shareholder returns, with the payment scheduled for August 20, 2025, following shareholder approval in June. This announcement may influence investor sentiment and reflects the company’s stable financial position.

Meilleure Health Reports 2024 Annual Results with Profit Amid Revenue Decline

Meilleure Health International Industry Group Limited announced its annual results for the year ended December 31, 2024, reporting a significant drop in revenue from HK$129.3 million in 2023 to HK$50.7 million in 2024. Despite the revenue decline, the company managed to achieve a profit of HK$32 million, down from HK$38.5 million the previous year, with notable gains from investment properties and other income streams. The results indicate challenges in sales but also highlight the company’s ability to leverage investment gains to maintain profitability.